Mandate

Vinge advises Symphony Technology Group in connection with the public offer for IBS

May 18, 2011

Vinge advises Symphony Technology Group in connection with the public offer for IBS AB, listed on NASDAQ OMX First North. Symphony Technology Group offers SEK 1.75 in cash per share in IBS, regardless of share class, and the board of directors of IBS has unanimously recommended the shareholders to accept the offer. Shareholders representing approximately 75.5 percent of the shares and 81.4 percent of the votes have irrevocably undertaken to accept the offer.

Vinge’s team consists of partner in charge Pontus Enquist as well as Emil Hedberg. In addition, Fabian Ekeblad has advised on banking and finance issues, and Johan Mattsson, Maria Eierborg, Moa Bergsten, Mikael Satama Granberg, Per Westman and Anders Frick, among other, have participated in the due diligence carried out on IBS.

Related

Vinge advises Fortinova Fastigheter AB (publ) on its first SEK 200 million green bond issue

Vinge has advised Fortinova Fastigheter AB (publ) (“Fortinova”) on the company’s first issue of senior unsecured green bonds in an aggregate principal amount of SEK 200 million, under a framework of up to SEK 600 million. Nordea, acted as sole bookrunner in connection with the bond issue.
September 18, 2026

Vinge advises Morrow Bank AB (publ) in connection with the bank’s sale of parts of MedMera Bank and the sale of NPL portfolios

Vinge has advised Morrow Bank AB (publ) in connection with the divestment of parts of MedMera Bank’s operations to a leading global credit investment firm. The divestment is structured as a sale of shares and priced at a premium of approximately SEK 90 million above equity value as per the completion date. The transaction includes parts of MedMera’s banking operations such as IT infrastructure, organisation and management, whilst Morrow Bank retains MedMera’s performing loans, deposits, customers, the MedMera brand, the Coop partnership agreement as well as key personnel.
September 15, 2026

Vinge advises HealthCap in conjunction with its investment in AMRA Medical

HealthCap is investing in AMRA Medical AB, a company that analyses whole-body MRI images to classify and quantify an individual’s muscle and fat tissue throughout the body and places this in relation to human health and disease.
September 15, 2026